A randomized, double-blind, placebo-controlled, phase III study of nonsteroidal aromatase inhibitors (anastrozole or letrozole) plus LY2835219, a CDK4/6 inhibitor, or placebo in postmenopausal women with hormone receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer with no prior systemic therapy in this disease setting.
Cancer Clinical Trials
Breast - Advanced ER (+) HER2 (-)
Monarch 3 (I3Y-MC-JPBM)
Breast - Bone Pain
Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention with Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim.
Breast - Metastatic, BRCA 1 and BRCA 2
A Phase 3 randomized placebo-controlled trial of carboplatin and paclitaxel with or without veliparib (ABT-888) in HER2-negative metastatirc or locally advanced unresectable BRCA-associated breast cancer.
Breast - Operable, HER2 (+)
A randomized, multicenter, open-label, phase III trial comparing trastuzumab plus pertuzumab plus a taxane following anthracyclines versus trastuzumab emtansine plus pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer.
ASBrS Nipple Sparing Mastectomy Registry.
A randomized, phase II, multicenter placebo-controlled study of ipatasertib (GDC-0068), an inhibitor of AKT, in combination with paclitaxel as front-line treatment for patients with metastatic triple-negative breast cancer.
Colorectal - Advanced
An open-label, multi-center, randomized phase 1B/2 study of PF-05212384 (PI3K inhibitor) plus 5-Fluorouracil-Leucovorin-Iriniotecan (FOLFIRI) versus Bevacizumab plus FOLFIRI in metastatic colorectal cancer.
City of Hope Registry
Molecular Genetics Studies of Cancer Patients and Their Relatives
Lung - Metastatic
Randomized, double blind, multicenter, phase III study comparing veliparib (ABT-888) plus carboplatin and paclitaxel versus placebo plus carboplatin and paclitaxel in previously untreated advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Lung - NSCLC
A phase IIIb/IV safety trial of Nivolumab (BMS-936558) in subjects with advanced or metastatic non-small cell lung cancer who have progressed during or after receiving at least one prior systemic regimen.
Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukemia (AML)
Connect® MDS and AML Registry
Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.
Solid Tumors (Metastatic Gastric, Melanoma, Mesothelioma or Urothelial Cancers) - Advanced
Merck EMR 100070-001
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biolocial and clinical activity of MSB0010718C (PD-L1 inhibitor) in subjects with metastatic or locally advanced solid tumors and expansion to selected indications.